At Visulytix, we have developed cutting-edge deep learning based AI solutions to completely change the fields of optometry and ophthalmology. Our mission is to provide essential information to clinical decision makers, enabling them to make the most effective decisions possible.
We deliver clinical decision support solutions which permit the early detection of sight threatening conditions. Ultimately, prompt detection results in the best possible outcomes, benefiting patients, providers and payers, whilst supporting the transition towards value based healthcare.
Pegasus is an AI decision support tool that works with fundus images or OCT volumes. For fundus images, Pegasus looks at a number of features within the image and provides the user with insights about the health of the optic disc, highlights detected features, as well as classifying diabetic retinopathy and macular diseases. Pegasus is capable of screening for major eye diseases such as glaucoma, and diabetic retinopathy. In addition, Pegasus’ macular anomaly tool can identify pathologies that can be consistent with DME, and wet or dry AMD.
For OCT, Pegasus looks at the 3D volume and is able to provide insights into the health of the macula by indicating signs of diseases such as AMD and DME – both chronic diseases that contribute significantly to the demand for eye care services worldwide.
Glaucoma is a degenerative eye condition, typically initiated by raised eye pressure. The optic nerve starts to develop damage, eventually resulting in irreversible loss of vision. Importantly, patients with glaucoma rarely experience symptoms, and it is therefore labelled the ‘silent thief of sight’. It is estimated that 80 million people will be suffering from glaucoma in 2020, and this will rise to 130 million by 2040. Early screening for glaucoma is essential, particularly if there is a family history of the condition.
Diabetic retinopathy is a complication of diabetes, a metabolic disorder whereby the body cannot regulate the level of blood glucose effectively. It is a worldwide problem, and the leading cause of blindness in patients between 20 and 64 years of age. The retina of the eye is usually affected, resulting in leakage of blood vessels and damage to the vision. Prompt recognition and treatment is paramount to minimize permanent sight loss.
AMD, is a degenerative eye disease affecting 5% of the population over 60. AMD is projected to affect 196 million people worldwide by 2020, and is characterized by abnormal changes in the macula – the central part of the retina that is extremely important for patients’ detailed vision. There are two main forms of AMD: the dry form and the more severe, sight threatening wet form. Early recognition of the disease is paramount to effective treatment. Once diagnosed, the disease is monitored with monthly scans which all currently need to be reviewed by an Eye specialist.
Diabetes can also affect the central part of the retina known as the macula. Through blood vessel leakage, deposits known as exudates can form, and the blood vessels leak to result in swelling of the macula region. This can drastically reduce a patient's central vision, and immediate treatment by an eye specialist is usually required.
UK Media & Investor Relations
+44 (0)20 7933 8780
+44 (0)79 8054 1893
+44 (0)78 4191 7679